Navigation Links
Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device
Date:1/19/2012

ANN ARBOR, Mich., Jan. 19, 2012 /PRNewswire/ -- Terumo Cardiovascular Systems announced today that it has entered into an exclusive agreement with LAAx, Inc. to distribute the TigerPaw® System II, a left atrial appendage closure device in the U.S.

The TigerPaw System II is indicated for occlusion of the left atrial appendage under direct visualization, in conjunction with other open cardiac procedures.  It is new to the market following successful completion of a clinical trial.  During its clinical trial the TigerPaw System II provided 100% occlusion at both post-op and at 90 days.

Mark Sutter, President and CEO of Terumo Cardiovascular Systems, stated, "This expansion of our product portfolio is another example of Terumo CVS's commitment to the CV OR market.  The distribution agreement provides us with an excellent product that provides advantages over other offerings on the market and that cardiac surgeons need today.  We are proud of this new partnership with LAAx, Inc."

Bill Wheeler, President and CEO of LAAx, Inc., added, "Terumo's broad distribution network will be a tremendous asset.  We will work together to get the TigerPaw System II into the hands of cardiac surgeons who have not yet had access to a clinically proven, 100% occlusive left atrial appendage (LAA) closure device. This clinical outcome expectation will benefit patients who need to reduce the medical risks associated with a less than 100% closure of the LAA.  We are happy to offer that option. Risk mitigation is an important consideration for every cardiac surgeon who considers 100% occlusion to be the only acceptable medical outcome for LAA occlusion technologies."

About Terumo Cardiovascular Systems Corporation 
Terumo Cardiovascular Systems Corporation manufactures and markets medical devices for the global cardiac surgery market and is the U.S. distributor for Vascutek® Vascular Grafts. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in Ann Arbor; Elkton, Maryland; and Ashland, Massachusetts. It is one of several subsidiaries of Terumo Corporation of Japan which focus on cardiac and vascular specialties, including Terumo Heart, Inc., developer of a ventricular assist device and Vascutek, Ltd., manufacturer of a broad portfolio of vascular grafts. For more information, visit www.terumo-cvs.com.

About LAAx, Inc.
LAAx, Inc. is a medical device company, located in Livermore, CA, whose purpose is to develop leading edge technology for the effective occlusion and/or exclusion of the left atrial appendage. Additionally, LAAx, Inc. is committed to maintaining effective systems to manage quality and quality objectives which translate technology into medical devices that are safe, serve the needs of the patient and the physician, and provide a viable business opportunity. LAAx, Inc.'s global goal is to make a positive impact on both the quality and effectiveness of healthcare delivered worldwide.

 


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Americas Holding Acquires Onset Medical Corporation, a Leader in Innovative Sheath Technology Designed for Multiple, Minimally Invasive Clinical Applications
2. Terumo Corporation, A Global Leader In Medical Device Technology, Celebrates 90th Anniversary
3. FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
4. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
5. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
6. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
7. Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
8. Terumo to Sponsor Presentations on Key Issues in Cardiac and Vascular Surgery at Society of Thoracic Surgeons Annual Meeting
9. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
10. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
11. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... und GERMANTOWN, Maryland , May ... mit Therawis bedient dringenden ... QIAGEN N.V. (NASDAQ: QGEN ... eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH ... Onkologie eingegangen zu sein. Ein erstes Projekt wird ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research Corp. ... their new reference materials that help researchers obtain ... collection to analyses. The rapid growth of the ... researchers to have standard methods to improve the ... Biases inherently exist at every step of the ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... , ... There are nearly 14.5 million people living with and beyond cancer ... June 5, 2016, communities around the world will gather to recognize these cancer survivors ... Survivors Day® is an annual worldwide Celebration of Life that is held on the ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising ... 550 employees of Sun Health Senior Living (SHSL) may not share those ... doctor and prescription copays for the year, while holding the line on increasing their ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... treatment for eating disorders, is opening a brand new child and adolescent residential ... 8-17 and their families with even more specialized eating disorder treatment and access ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic surgeon and ... of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International Conference ... 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on stem ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Bunion ... knowns as a bunionette) treatment was more than humbled by customer demand over the ... of their SKU's mid sale. Now that Bunion Bootie has completely replenished its inventory ...
Breaking Medicine News(10 mins):